⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118635 | 0.90 | EGFR (0.34) | — | |
| Pyrimidine SCHEMBL28805849 | 0.90 | EGFR (0.38) | — | |
| SCHEMBL6873399 | 0.89 | EGFR (0.33) | — | |
| SCHEMBL29259056 | 0.83 | BRD4 (0.31) | — | |
| SCHEMBL31072932 | 0.74 | EGFR (0.34) | — | |
| SCHEMBL16576782 | 0.71 | FTO (0.38) | — | |
| SCHEMBL29937163 | 0.71 | EGFR (0.35) | — | |
| SCHEMBL8122154 | 0.66 | CYP2A6 (0.46) | — | |
| SCHEMBL2040833 | 0.65 | DYRK1A (0.43) | — | |
| SCHEMBL6112147 | 0.65 | DYRK1A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2613 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3185329-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2026-04-22 | — | — | EP | claimed |
| US-20260042772-A1 | FURO PYRIMIDINE DERIVATES | MERCK PATENT GMBH (DE) | 2026-02-12 | — | — | US | claimed |
| US-12410180-B2 | Light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2025-09-09 | — | — | US | claimed |
| US-20250163032-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2025102016-A1 | NOVEL MOLECULES AS INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| CN-115279357-B | Pharmaceutical composition containing hydroxyurea for inhibiting inflammatory reaction | 拜耳诺克斯有限公司 | 2024-08-09 | — | — | CN | claimed |
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | claimed |
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | claimed |
| EP-3185328-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2024-05-22 | — | — | EP | claimed |
| EP-3185332-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2024-05-01 | — | — | EP | claimed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| WO-2005092896-A1 | COMPOUND FOR INHIBITING TYROSINE KINASE ACTIVITY OF DDR2 PROTEIN | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2005-10-06 | — | — | WO | claimed |
| WO-2005077955-A1 | DERIVATIVES OF 1,4-DIAZABICYCLO[3.2.1]OCTANECARBOXAMIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-08-25 | — | — | WO | claimed |
| EP-1551341-A2 | USE OF Y-27632 AS AN AGENT TO PREVENT RESTENOSIS AFTER CORONARY ARTERY ANGIOPLASTY/STENT IMPLANTATION | The Trustees of Columbia University in the City of New York (US) | 2005-07-13 | — | — | EP | claimed |
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040028716-A1 | Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2004-02-12 | — | — | US | claimed |
| WO-2003105923-A2 | USE OF Y-27632 AS AN AGENT TO PREVENT RESTENOSIS AFTER CORONARY ARTERY ANGIOPLASTY/STENT IMPLANTATION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | claimed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | claimed |